Tempest Therapeutics Jumps Over 3,900% on Wednesday As Liver-Cancer Treatment Shows Promise

Dow Jones2023-10-12

Shares of Tempest Therapeutics Inc. (TPST) soared more than 3,900% during the trading hours but crashed over 34% in extended trading on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.

The drug candidate, in combination with the Roche Holding AG (RHHBY) treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.

Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said.

Hepatocellular carcinoma is an aggressive cancer that researchers expect to become the third leading cause of cancer death by 2030.

Tempest on Wednesday also announced a limited duration stockholder rights plan, or "poison pill," exercisable only if an entity offers to acquire 10% or more of the company's outstanding common stock.

The plan was not adopted in response to a specific takeover threat, Tempest said in a release, but is intended "to enable all of our stockholders to realize the long-term value of their investment."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

7

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2374642548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-12 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2374642548","market":"us","top_or_hot":-1,"title":"Tempest Therapeutics Jumps Over 3,900% on Wednesday As Liver-Cancer Treatment Shows Promise","media":"Dow Jones","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/TPST\">Tempest Therapeutics Inc.</a> (TPST) soared more than 3,900% during the trading hours but crashed over 34% in extended trading on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c6f56755fa8525a9109f08ee89c39e8\" tg-width=\"265\" tg-height=\"114\"/></p><p>The drug candidate, in combination with the Roche Holding AG (RHHBY) treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.</p><p>Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said.</p><p>Hepatocellular carcinoma is an aggressive cancer that researchers expect to become the third leading cause of cancer death by 2030.</p><p>Tempest on Wednesday also announced a limited duration stockholder rights plan, or &#34;poison pill,&#34; exercisable only if an entity offers to acquire 10% or more of the company&#39;s outstanding common stock.</p><p>The plan was not adopted in response to a specific takeover threat, Tempest said in a release, but is intended &#34;to enable all of our stockholders to realize the long-term value of their investment.&#34;</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest Therapeutics Jumps Over 3,900% on Wednesday As Liver-Cancer Treatment Shows Promise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest Therapeutics Jumps Over 3,900% on Wednesday As Liver-Cancer Treatment Shows Promise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-12 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tempest Therapeutics Inc. (TPST) soared more than 3,900% during the trading hours but crashed over 34% in extended trading on Wednesday after the company released study results for its ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2374642548","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2374642548","pubTimestamp":1697069035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Tempest Therapeutics Inc.   soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.The drug candidate, in combination with the Roche Holding AG  treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said.Hepatocellular carcinoma is an aggressive cancer that researchers expect to become the third leading cause of cancer death by 2030.Tempest on Wednesday also announced a limited duration stockholder rights plan, or \"poison pill,\" exercisable only if an entity offers to acquire 10% or more of the company's outstanding common stock.The plan was not adop","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Tempest Therapeutics周三股价上涨3,900%，肝癌治疗显示出前景","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"Shares of Tempest Therapeutics Inc. (TPST) soared more than 3,900% during the trading hours but crashed over 34% in extended trading on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.The drug candidate, in combination with the Roche Holding AG (RHHBY) treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.Patients treated with the triple therapy had median progression-free survival of seven months, versus 4.3 months for those treated only with Tecentriq and Avastin, Tempest said.Hepatocellular carcinoma is an aggressive cancer that researchers expect to become the third leading cause of cancer death by 2030.Tempest on Wednesday also announced a limited duration stockholder rights plan, or \"poison pill,\" exercisable only if an entity offers to acquire 10% or more of the company's outstanding common stock.The plan was not adopted in response to a specific takeover threat, Tempest said in a release, but is intended \"to enable all of our stockholders to realize the long-term value of their investment.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":7,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2374642548"}